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three patients; no complete/partial responses according to 
RECIST). Median overall survival was 17.1 weeks (95% 
CI, 6.3–not achievable). No serious emibetuzumab-related 
adverse events or new safety signals emerged. Grade ≥ 3 
possibly drug-related adverse events were hyperkalemia, 
hyponatremia, and hyperuricemia (one each). Emibetuzum-
ab’s pharmacokinetics profile was similar to that observed 
previously. MET expression and clinical outcomes were not 
obviously associated.
Conclusion Emibetuzumab was well tolerated with limited 
single-agent activity in advanced gastric adenocarcinoma.
Keywords Antibodies, monoclonal, humanized · Clinical 
trial · Phase II · LY2875358 · MET protein, human · 
Stomach neoplasms
Abstract 
Purpose Mesenchymal–epithelial transition factor (MET) 
is expressed in gastric cancer and associated with poor clini-
cal outcomes. We assessed activity, safety, and pharmacoki-
netics of emibetuzumab, a bivalent monoclonal anti-MET 
antibody that blocks ligand-dependent and ligand-independ-
ent MET signaling.
Methods This non-randomized, single-arm, Phase 2 
study enrolled Asian patients with MET diagnostic positive 
advanced gastric adenocarcinoma. Emibetuzumab (2000 mg, 
intravenous) was given on days 1 and 15 (28-day cycle). The 
primary endpoint was 8-week progression-free survival rate. 
Secondary objectives included safety, pharmacokinetics, 
overall survival, and change in tumor size.
Results Tumors from 65 patients were immunohistochemi-
cally screened to enroll 15 MET diagnostic positive patients 
(23% positivity; 8 Japanese, 7 Korean; 10 male). Eight-week 
progression-free survival rate was 0.47 (70% CI, 0.33–0.59). 
Disease control rate was 40% (target lesion decreases, 
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Introduction
The mesenchymal–epithelial transition factor (MET) recep-
tor is a tyrosine kinase receptor and its only known ligand 
is hepatocyte growth factor (HGF). HGF/MET signaling is 
involved in embryogenesis and responses to tissue damage, 
and MET is broadly expressed in normal adult tissues [1]. 
Activation of MET signaling can occur via a ligand-depend-
ent mechanism, by HGF, or ligand-independent mechanisms, 
including overexpression of the MET protein, amplification 
of the MET gene (c-met), or c-met mutations [1, 2]. Aberrant 
MET signaling has been described to be involved in tumor 
growth and invasion, angiogenesis, metastasis, and resistance 
to therapy [1–3]. MET expression has been reported in many 
tumor types, including gastric cancer [3]. It has been suggested 
that c-met amplification and overexpression of MET protein in 
gastric cancer correlate with poor patient outcomes [4]. Clini-
cal studies with MET-targeting agents have demonstrated a 
role for MET as a predictive biomarker in patients with gastric 
cancer [5].
Emibetuzumab is a humanized immunoglobulin G4 mono-
clonal bivalent anti-MET antibody that blocks MET signaling 
via two distinct mechanisms: it suppresses ligand-dependent 
MET activation by blocking HGF interaction with the recep-
tor, and it suppresses ligand-independent MET activation by 
causing the MET receptor to be internalized and degraded [6]. 
Pre-clinical research has shown that emibetuzumab inhibits 
MET-expressing gastric cancer cell line proliferation in vitro 
and in vivo when given as monotherapy or in combination 
with chemotherapy [7]. In Phase 1 dose escalation studies, 
emibetuzumab monotherapy was well tolerated in patients 
with advanced solid tumors, including gastric cancer, with no 
dose-limiting toxicities (Studies JTBA and JTBD) [8, 9]. Emi-
betuzumab activity in patients with advanced gastric cancer 
has not previously been evaluated, and there is limited infor-
mation on biomarkers that might help identify patients with 
gastric cancer who will respond to emibetuzumab treatment.
The aim of this Phase 2 study was to explore the antitu-
mor activity, safety, and pharmacokinetics of emibetuzumab 
in patients with advanced gastric or gastroesophageal junc-
tion (GEJ) adenocarcinoma selected for positive MET tumor 
expression (MET diagnostic positive). The primary objec-
tive of the study was to evaluate emibetuzumab activity in 
terms of 8-week progression-free survival (PFS) rate relative 
to historical control.
Materials and methods
Study design
This study was a non-randomized, open-label, single-arm, 
Phase 2 study of emibetuzumab in Japanese and Korean 
patients with MET diagnostic positive advanced gastric 
or GEJ adenocarcinoma conducted in 12 study centers 
between October 2013 and December 2014 (Study JTBE). 
The study was registered at http://www.clinicaltrials.gov 
(NCT01874938). The study protocol conformed to the 
Declaration of Helsinki and the International Conference 
of Harmonisation Good Clinical Practice guidelines, and 
was approved by the ethics review board at each study 
site. All patients provided written informed consent to 
provide a tissue sample for prescreening for diagnosis 
of MET expression status and to undergo study-specific 
procedures.
Study population
Patients with a diagnosis of histopathologically or cyto-
logically confirmed gastric or GEJ adenocarcinoma, who 
had locally advanced and/or metastatic disease that was 
unresectable, were ≥ 20 years, and had not previously been 
treated with any HGF-/MET-targeting therapeutics, were 
screened for eligibility for the study. As a prescreening 
step, patients’ tumor samples were tested for MET protein 
expression status by immunohistochemistry (IHC). Archi-
val tumor tissues, or biopsy samples taken at prescreen-
ing, were tested for MET protein expression status by IHC 
at an Eli Lilly and Company central laboratory using the 
A2H2-3 diagnostic anti-MET antibody [10]. Patients were 
eligible if they were MET positive, which was defined as 
≥ 60% of tumor cells staining at 2 + or 3 + intensity for 
MET.
Patients who were identified to be MET diagnostic posi-
tive were further screened for enrollment using the following 
inclusion criteria: two prior chemotherapy regimens con-
taining fluoropyrimidine and platinum agents for gastric or 
GEJ adenocarcinoma; measurable disease as defined by the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 [11]; adequate organ function; and performance 
status of ≤ 1 on the Eastern Cooperative Oncology Group 
scale. Exclusion criteria included: active fungal, bacterial, 
and/or known viral infection; heart failure classified New 
York Heart Association class ≥ 3, unstable angina, or myo-
cardial infarction in the previous 6 months; and a corrected 
QT interval of > 470 ms on the screening electrocardiogram.
Study treatment
Patients received emibetuzumab 2000 mg using a flat dosing 
scheme, by intravenous infusion over 150 min on day 1 and 
day 15 of a 28-day cycle. Treatment was continued until at 
least one discontinuation criterion was met [eg, progressive 
disease (PD), unacceptable toxicity].
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Clinical assessments
Tumor response and progression were evaluated using 
RECIST version 1.1, and graded adverse events (AEs) 
using the National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.03. To determine 
serum concentrations of emibetuzumab, blood samples 
were collected before drug infusion and at the end of drug 
infusion on day 1 and day 15 during each of the first four 
cycles.
Primary and secondary outcome measures
The primary efficacy measure of the study was the PFS 
rate at 8 weeks + 3 days. The timepoint for PFS rate was 
set at 8 weeks + 3 days, because tumor measurement at 
8 weeks was done 3 days before or after 8 weeks, but it 
is referred to hereafter as 8 weeks. The secondary meas-
ures were: disease control rate (DCR), overall response 
rate, duration of response, overall survival (OS), PFS, best 
percentage change in tumor size, drug safety [assessed by 
AEs], and pharmacokinetic properties of the drug (serum 
concentrations at each sampling point).
Exploratory biomarker analyses
For the exploratory biomarker analysis, MET protein 
expression in MET diagnostic positive patients was fur-
ther categorized as high MET or low MET by different 
cut points for high expression. Levels of MET protein 
expression were assessed using a semi-quantitative scor-
ing scheme that incorporated both the staining inten-
sity and the percentage of cells displaying each level of 
staining intensity. These assessments were used to cal-
culate the H-score for the cell membrane, as follows: 
H-score = 1 × (% of cells staining at 1 +) + 2 × (% of cells 
staining at 2 +) + 3 × (% of cells staining at 3 +) [12]. 
The cut points investigated for high MET or low MET 
among MET diagnostic positive patients were: > 30% of 
cells staining at 3 + intensity and H-score > 210 in the 
membrane; > 30% of cells staining at 3 + intensity in the 
membrane; H-score > 210 in the membrane; ≥ 80% of cells 
staining at ≥ 2 + intensity in the membrane; and 100% of 
cells staining at ≥ 2 + intensity in the membrane.
Fluorescence in situ hybridization (FISH) was used to 
assess c-met and epidermal growth factor receptor gene 
(EGFR) amplification of tumor samples using two different 
definitions of each. First, the number of cells with ampli-
fication was analyzed and tumor samples were considered 
amplified if ≥ 40% of the cells counted had ≥ 4 signals. 
Second, the ratio of cells with amplification was measured 
and tumor samples were considered amplified if the average 
number of signals divided by the average number of signals 
from the chromosome enumeration probe (CEP7) was ≥ 2.
Sample size and statistical analyses
A sample size of 15 was determined, based on feasibility 
and the design of a previous Phase 1 study of emibetuzumab 
conducted in mostly Caucasian patients with advanced 
solid tumors (Study JTBA) [13]. This sample size provides 
a 78.6% power based on a one-sample test with one-sided 
type I error of 0.15 when the expected and threshold PFS 
rates at 8 weeks are assumed as 0.63 and 0.40, respectively.
Clinical activity and safety analyses were conducted for 
all patients who received at least one dose of emibetuzumab. 
For clinical activity parameters, point estimates and confi-
dence intervals (CIs) were obtained. PFS rate was calculated 
using the Kaplan–Meier method. To address the primary 
objective, the lower limit of the two-sided 70% CI of the 
PFS rate at 8 weeks was compared with the threshold value 
of 0.40 to determine whether this limit was greater than the 
threshold value. For safety, AEs were summarized as the 
number and percentage of patients for whom each event was 
reported. SAS 9.2 (SAS Institute, Cary, NC, USA) was used 
for all statistical analyses.
Results
Patient disposition and baseline characteristics
In total, 65 patients from 12 study sites (7 in Japan, 5 in 
Korea) were prescreened for diagnosis of MET protein 
expression status. Of these patients, 22 were identified as 
being MET diagnostic positive (≥ 60% of tumor cells stain-
ing at 2 + or 3 + intensity for MET)—a MET diagnostic 
positive rate of 34% (22 of 65 patients). Seven of these 22 
patients were not enrolled owing to patient decision (two 
patients), physician decision (two patients), sponsor deci-
sion (one patient, for whom prior therapy was ongoing and 
data on disease progression were incomplete at time of study 
enrollment), death due to study disease (one patient), or 
meeting the exclusion criterion of having an active fungal, 
bacterial, and/or known viral infection (one patient).
All 15 enrolled patients had an initial diagnosis of gastric 
adenocarcinoma; the majority were male, and the median 
patient age was 63 years (Table 1). All had received prior 
systemic therapy, with at least three prior therapies (range 
3–5); six had received prior surgery, and one had received 
prior radiotherapy.
The median number of cycles of emibetuzumab given 
(one or both of the day 1 and day 15 doses administered) 
was 2 (range 1–10), and the median number of cycles 
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completed (day 1 and day 15 doses both administered) 
was 2. Six patients completed one cycle, three completed 
two cycles, two completed three cycles, two completed 
five cycles, and one completed nine cycles; only one 
patient did not complete any cycles. The study treatment 
was discontinued for all 15 patients, either because of PD 
(14 patients) or death due to study disease (one patient). 
Six patients had post-discontinuation therapy; for five 
patients, this was systemic therapy, and for one patient, it 
was radiotherapy.
Clinical activity
The PFS rate at 8 weeks—the primary endpoint of this 
study—was 0.47 (70% CI, 0.33–0.59; Fig. 1a); the lower 
confidence limit did not exceed the prespecified thresh-
old of 0.40. The median PFS was 8.3 weeks (95% CI, 
Table 1  Patient demographics 
and baseline characteristics
BMI body mass index, ECOG Eastern Cooperative Oncology Group, GEJ gastroesophageal junction
a Target lesions that were present and measured at screening (detected by computed tomography)
b Non-gastric target lesions that were present and measured at screening (detected by computed tomogra-
phy)
c Locations of non-gastric target lesions that were present and measured at screening (detected by com-
puted tomography); locations were: liver, lymph node, ovary, peritoneum, rectouterine pouch, spleen, lung, 
colon, colorectal, bladder, periaortic
Variable N = 15
Age, median (min–max) (years) 63 (39–74)
Male, n (%) 10 (67)
Country, n (%)
 Japan (three sites) 8 (53)
 Korea (three sites) 7 (47)
ECOG performance status, n (%)
 0 1 (7)
 1 14 (93)
Height, median (min–max) (cm) 164.5 (150.8–178.2)
Weight, median (min–max) (kg) 55.2 (39.5–75.6)
BMI, median (min–max) (kg/m2) 21.0 (17.2–25.4)
Pathological diagnosis at initial diagnosis, n (%)
 Gastric adenocarcinoma 15 (100)
 GEJ adenocarcinoma 0
Prior therapies, n (%)
 Systemic therapy 15 (100)
 Surgery 6 (40)
 Radiotherapy 1 (7)
Number of measurable lesions (target lesions), n (%)a
 1 2 (13)
 2 8 (53)
 3 4 (27)
 4 1 (7)
Number of metastatic lesions (non-gastric target lesions), n (%)b
 1 3 (20)
 2 7 (47)
 3 4 (27)
 4 1 (7)
Number of metastatic sites (non-gastric target lesions), n (%)c
 1 9 (60)
 2 4 (27)
 3 1 (7)
 4 1 (7)
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4.14–12.14; Fig. 1a) and median OS was 17.1 weeks (95% 
CI, 6.3 to not achievable; Fig. 1b).
A total of six patients had a best overall response of stable 
disease during emibetuzumab monotherapy, resulting in a 
DCR of 40% (95% CI, 16–68%). No complete responses 
(CRs) or partial responses (PRs) according to RECIST were 
observed. The best percentage change in tumor size ranged 
from − 22.4 to 32.1%, and shrinkage in target lesions was 
observed in three patients (Fig. 2).
Safety and tolerability measures
Emibetuzumab demonstrated a favorable safety profile 
and was well tolerated. Twelve patients (80%) experienced 
≥ 1 AEs that were considered possibly study drug-related 
(Table 2). The most commonly reported possibly emibet-
uzumab-related AEs of any grade were constipation and 
hypoalbuminemia [three patients (20%) each; Table 2] and 
were all of mild or moderate severity. The only possibly 
emibetuzumab-related Grade ≥ 3 AEs reported were one 
case each of hyperkalemia (Grade 3), hyponatremia (Grade 
3), and hyperuricemia (Grade 4) (the latter two AEs occurred 
in one patient).
No AEs led to treatment discontinuation or death. Seri-
ous AEs were observed in six patients (40%), of which none 
were considered related to emibetuzumab. For three patients 
(20%), there was a dose delay due to an AE, including one 
AE that the investigator considered at least possibly related 
to emibetuzumab (hyperkalemia). An abnormal value of 
QTcF (Fridericia’s QT correction) exceeding 500 ms and 
an increase of QTcF > 60 ms from baseline was observed in 
two Japanese patients at a single timepoint (one pre-dose and 
one post-dose). Both prolongations were observed at only 
one visit and no coinciding clinical symptoms related to QTc 
prolongation were reported (i.e., no arrhythmia, fainting, and 
sudden death).
Fig. 1  Kaplan–Meier analyses 
of progression-free survival (a) 
and overall survival (b)
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Pharmacokinetics
The serum concentration of emibetuzumab reached steady 
state in about 2–3 months (Fig. 3).
Biomarker status and clinical outcomes
Tumor samples from nine patients were tested by both IHC 
and FISH. MET expression by IHC (using the threshold of 
> 30% of cells staining at 3 + intensity and H-score > 210 
in the membrane) was categorized as high for four of these 
patients. Using FISH ratio and FISH count thresholds for 
c-met amplification (average number of c-met signals divided 
by average number of signals from CEP7 ≥ 2, and ≥ 40% of 
cells counted having ≥ 4 c-met signals, respectively), c-met 
was amplified for three of the four patients with high MET 
expression by IHC, and c-met was unamplified for all five 
of those with low MET expression by IHC. The association 
between high/low MET status and amplified/unamplified 
c-met status was significant, irrespective of whether the ratio 
or count definition was used for determining FISH amplifica-
tion status (Fisher exact test, both P = 0.048).
The small sample size of the study precluded the possi-
bility of making a thorough assessment of the associations 
observed between biomarker status and clinical outcomes. 
Exploratory analysis did not show any difference in median 
PFS between patients classified as having high MET expres-
sion based on IHC and/or FISH using different cut points for 
high/low MET expression (Fig. 4).
EGFR amplification was observed in four out of nine 
patients’ tumor samples tested based on the cell count defini-
tion for amplification. Co-amplification of c-met and EGFR 
was observed in two out of these four tumor samples with 
EGFR amplification. None of the tumor samples showed 
EGFR focal amplification based on the ratio definition. 
No significant difference in median PFS was observed in 
patients with or without c-met or EGFR amplification by 
FISH ratio or FISH count.
Fig. 2  Waterfall plot showing percentage change in lesion size 
from baseline at best response and best overall response category 
for each patient. Tumors were considered not evaluable (according 
to RECIST) in patients with SD whose only post-baseline measure-
ment occurred < 6 weeks after the first dose of emibetuzumab. The 
best overall response was SD for patient 11 and was not evaluable for 
patient 12. For patient 15, the best overall response was PD despite 
best change from baseline being − 22.4% because of a new lesion 
(malignant ascites). EGFR epidermal growth factor receptor, MET 
mesenchymal–epithelial transition factor, PD progressive disease, 
RECIST response evaluation criteria in solid tumors, SD stable dis-
ease
Table 2  Overview of AEs (N = 15)
AE adverse event
Category of AE Patients with ≥ 1 AE n (%)
Any grade Grade ≥ 3
Regardless of causality 14 (93) 8 (53)
Related to emibetuzumab 12 (80) 2 (13)
 Constipation 3 (20) 0 (0)
 Hypoalbuminemia 3 (20) 0 (0)
 Diarrhea 2 (13) 0 (0)
 Hyperkalemia 2 (13) 1 (7)
 Hyperuricemia 2 (13) 1 (7)
 Hypocalcemia 2 (13) 0 (0)
 Hyponatremia 2 (13) 1 (7)
 Insomnia 2 (13) 0 (0)
 Nausea 2 (13) 0 (0)
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Discussion
This is the first study of emibetuzumab in patients with 
advanced gastric cancer selected for MET diagnostic posi-
tive status. Given as monotherapy to Asian patients with 
gastric cancer who had received two lines of prior cytotoxic 
therapy, emibetuzumab was well tolerated. However, even 
though the PFS rate at 8 weeks was 0.47, the study did not 
meet its prespecified primary endpoint as the lower confi-
dence limit for this value did not exceed the threshold value 
of 0.40.
Fig. 3  Serum concentrations 
of emibetuzumab before and 
after infusion of 2000-mg emi-
betuzumab during the first four 
cycles of therapy. A line within 
the box marks the median, 
and the boundaries of the box 
indicate the 75th and 25th 
percentiles. Whiskers above and 
below the box indicate the 90th 
and 10th percentiles
Fig. 4  Forest plot of hazard ratios for progression-free survival by 
biomarker status. Abbreviations: c-met gene encoding MET, EGFR 
gene encoding  epidermal growth factor receptor, FISH fluorescence 
in  situ hybridization, IHC immunohistochemistry, MET mesenchy-
mal–epithelial transition factor, NA not applicable, PFS progression-
free survival
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MET has been described as a negative prognostic marker 
for gastric cancer. In a recent meta-analysis that included 
data from more than 8000 patients with gastric cancer, IHC-
determined MET overexpression was significantly corre-
lated with aggressive tumor behavior [14]. In our study, all 
patients were MET diagnostic positive, which underscores 
the fact that the patient population selected for this trial 
should be considered as having an unfavorable prognosis. 
Still, 6 of 15 patients had a best overall response of stable 
disease, which corresponded to a DCR of 40%. The inter-
pretation of this result is clearly limited by the absence of 
a control arm in our proof-of-concept study. However, it 
is possible that the aggressive tumor phenotype associated 
with MET expression might have contributed to the limited 
single-agent activity of emibetuzumab. Tumor shrinkage 
was observed in individual patients (three of 15 patients), 
but no CRs or PRs were observed for monotherapy in this 
study. Single-agent activity of MET-targeting agents has 
been described previously. In a Phase 2 study of patients 
with metastatic gastric cancer who received foretinib, an 
oral multikinase inhibitor that also targets MET, the best 
response was stable disease (achieved by 23 and 20% of 
patients who received intermittent dosing and daily dos-
ing, respectively) [15]. In a Phase 2 study of patients with 
metastatic gastric cancer who received tivantinib, a selec-
tive inhibitor of c-met, no objective response was observed, 
and the DCR was 36.7% [16]. The reason for the limited 
single-agent activity of MET-targeting agents in gastric 
cancer remains to be elucidated; however, a growing body 
of evidence suggests that activity of these agents might be 
restricted to a well-defined patient population selected by 
biomarker strategies to enrich for patients with sensitivity to 
MET-targeting agents [17]. This could encompass selection 
of patients with the highest MET expression and/or c-met 
amplification.
In our study, we observed a statistically significant associ-
ation between c-met amplification and high MET expression, 
with three patients harboring a c-met amplification among 
the four patients with the highest MET expression (H-score 
≥ 210). This finding suggests that both FISH and IHC might 
be appropriate methods for identifying a similar patient pop-
ulation depending on the cut point used. However, explora-
tory biomarker analyses assessing different dichotomous cut 
points for MET expression did not reveal any clear statisti-
cally significant relationship between MET expression and 
clinical outcomes. In part, this may be because of the small 
sample size of 15 patients in this study, but could also reflect 
the need for additional or complementary biomarkers for 
patient selection.
According to the literature, the activity of MET-target-
ing agents might be restricted to patients in whom MET is 
the sole driver of the disease [17]. As downstream signal-
ing pathways common to MET and the human epidermal 
growth factor receptor (HER) family partially overlap, it has 
been hypothesized that the effect of MET inhibition could 
be neutralized or attenuated by parallel activation of HER 
family receptors, such as epidermal growth factor receptor 
[18]. In our study, there were interesting anecdotal observa-
tions in line with this hypothesis for some patients. Out of 
the three patients enrolled in our study who were harboring 
c-met amplification and corresponding high MET protein 
expression (H-score ≥ 210), two did not show any reduction 
in target lesions following emibetuzumab treatment (Fig. 2, 
patients 1 and 3), and both were diagnosed as having tumors 
with co-amplification of EGFR. In contrast, the only patient 
with c-met amplification, but no EGFR amplification, was 
the patient with the greatest reduction in target lesions in our 
study (Fig. 2, Patient 15). Despite a − 22.4% change in tumor 
size from baseline, the patient was discontinued at the end 
of Cycle 2 because of PD based on a new liver lesion. This 
mixed response suggests that the target lesions, at least, in 
this patient might have been MET-dependent and sensitive 
to MET-targeted emibetuzumab therapy as hypothesized 
for MET-amplified tumors without concomitant EGFR 
signaling.
Concomitant c-met and EGFR amplification and activa-
tion of extensive crosstalk between HER and MET receptors 
have been reported to be sources of drug resistance in gastric 
cancer [19, 20]. Amplification of c-met is observed in 4–12% 
of gastric cancer patients and concomitant c-met and EGFR 
amplification (or overexpression of the respective proteins) 
has been reported in up to 6% of gastric cancer cases [21, 
22]. Therapeutic strategies that have been suggested as 
promising options for patients with high MET expression 
or c-met amplification, to overcome primary and acquired 
drug resistance, include combination therapies that target 
MET and EGFR, as well as therapies utilizing tetraspecific 
antibodies [18–20]. For example, monotherapy with MET 
inhibitors was found to induce tumor growth inhibition only 
in a cohort of patient-derived xenografts from a poorly dif-
ferentiated adenocarcinoma of the GEJ with c-met ampli-
fication, but no EGFR molecular alterations. In contrast, 
concomitant MET/EGFR inhibition resulted in complete 
tumor regression and prevented the onset of resistance in 
this cohort of patient-derived xenografts with c-met ampli-
fication, but no EGFR molecular alterations [18].
In addition, combination of standard of care chemo-
therapy regimens and antibodies targeting MET signaling 
have been studied. However, the results of late stage trials 
for the anti-HGF antibody rilotumumab and the monova-
lent anti-MET antibody onartuzumab in combination with 
chemotherapy did not show a survival benefit [17, 23, 24]. 
There are several possible explanations for the negative 
results obtained with these antibodies (which, in contrast 
to emibetuzumab, only block ligand-dependent but not 
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ligand-independent MET signaling), including failure to 
identify the appropriate target population for these com-
pounds [17].
Emibetuzumab had a favorable safety profile in our study 
as in the previous studies and there were no new unexpected 
safety findings. The reported emibetuzumab-related AEs 
were mostly mild or moderate in intensity and the most 
common were hypoalbuminemia (a known class effect for 
agents targeting MET or HGF) [25–27] and constipation. 
Only three emibetuzumab-related Grade ≥ 3 AEs were 
reported (hyperkalemia, hyponatremia, and hyperuricemia). 
No thromboembolic events were observed, whereas these 
events have been reported for the monovalent anti-MET anti-
body onartuzumab [28].
The pharmacokinetic profile of emibetuzumab in this 
Asian study population was similar to the profiles observed 
in the previous studies of emibetuzumab monotherapy, 
which were conducted in the United States with mostly Cau-
casian patients and supported a 2-week dosing schedule [29, 
30]. Analysis of the pharmacokinetic data from this study 
is underway and the data will be combined with data from 
other studies in a population pharmacokinetics report.
One limitation of this report is the small sample size, 
and the non-randomized, single-arm study design, which has 
known inferential deficiencies. However, the study design 
was appropriate for assessing the primary endpoint of PFS 
rate at 8 weeks in a limited number of patients to explore 
putative evidence of antitumor activity in the selected patient 
population.
In conclusion, although the study did not meet its primary 
endpoint, emibetuzumab was well tolerated and showed lim-
ited single-agent activity in Asian patients with advanced 
gastric adenocarcinoma. Further investigation, including 
complementary biomarkers to identify patients with gastric 
cancer who are most likely to benefit from emibetuzumab 
single-agent therapy, is warranted. Given the favorable 
safety profile, combination strategies with other therapeutic 
agents in patients with MET-positive gastric cancer appear 
feasible and might provide strategies for improving the activ-
ity of emibetuzumab in this patient population in the future.
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